177 related articles for article (PubMed ID: 32841462)
1. Evaluating functional disability in clinical trials of lisdexamfetamine dimesylate in binge eating disorder using the Sheehan Disability Scale.
Yee KS; Pokrzywinski R; Hareendran A; Shaffer S; Sheehan DV
Int J Methods Psychiatr Res; 2021 Mar; 30(1):e1849. PubMed ID: 32841462
[TBL] [Abstract][Full Text] [Related]
2. Time course of the effects of lisdexamfetamine dimesylate in two phase 3, randomized, double-blind, placebo-controlled trials in adults with binge-eating disorder.
McElroy SL; Hudson JI; Gasior M; Herman BK; Radewonuk J; Wilfley D; Busner J
Int J Eat Disord; 2017 Aug; 50(8):884-892. PubMed ID: 28481434
[TBL] [Abstract][Full Text] [Related]
3. A psychometric analysis and revalidation of the Yale-Brown Obsessive Compulsive Scale modified for Binge Eating in adults with binge eating disorder.
Yee K; Serrano D; Kando J; McElroy SL
Qual Life Res; 2019 Dec; 28(12):3385-3394. PubMed ID: 31473907
[TBL] [Abstract][Full Text] [Related]
4. Clinical Characteristics and Treatment Response to Lisdexamfetamine Dimesylate Versus Placebo in Adults With Binge Eating Disorder: Analysis by Gender and Age.
Kornstein SG; Bliss C; Kando J; Madhoo M
J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30817099
[TBL] [Abstract][Full Text] [Related]
5. Lisdexamfetamine Dimesylate Effects on Binge Eating Behaviour and Obsessive-Compulsive and Impulsive Features in Adults with Binge Eating Disorder.
McElroy SL; Mitchell JE; Wilfley D; Gasior M; Ferreira-Cornwell MC; McKay M; Wang J; Whitaker T; Hudson JI
Eur Eat Disord Rev; 2016 May; 24(3):223-31. PubMed ID: 26621156
[TBL] [Abstract][Full Text] [Related]
6. Relationships between clinical scales and binge eating days in adults with moderate to severe binge eating disorder in two Phase III studies.
Citrome L; Kando JC; Bliss C
Neuropsychiatr Dis Treat; 2018; 14():537-546. PubMed ID: 29497297
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial.
Hudson JI; McElroy SL; Ferreira-Cornwell MC; Radewonuk J; Gasior M
JAMA Psychiatry; 2017 Sep; 74(9):903-910. PubMed ID: 28700805
[TBL] [Abstract][Full Text] [Related]
8. Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial.
Guerdjikova AI; Mori N; Blom TJ; Keck PE; Williams SL; Welge JA; McElroy SL
Hum Psychopharmacol; 2016 Sep; 31(5):382-91. PubMed ID: 27650406
[TBL] [Abstract][Full Text] [Related]
9. Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials.
McElroy SL; Hudson J; Ferreira-Cornwell MC; Radewonuk J; Whitaker T; Gasior M
Neuropsychopharmacology; 2016 Apr; 41(5):1251-60. PubMed ID: 26346638
[TBL] [Abstract][Full Text] [Related]
10. Validation of the yale-brown obsessive compulsive scale modified for binge eating.
Deal LS; Wirth RJ; Gasior M; Herman BK; McElroy SL
Int J Eat Disord; 2015 Nov; 48(7):994-1004. PubMed ID: 26032442
[TBL] [Abstract][Full Text] [Related]
11. Effects of Lisdexamfetamine Dimesylate on Functional Impairment Measured on the Sheehan Disability Scale in Adults With Moderate-to-severe Binge Eating Disorder: Results from Two Randomized, Placebo-controlled Trials.
Sheehan DV; Gasior M; McElroy SL; Radewonuk J; Herman BK; Hudson J
Innov Clin Neurosci; 2018 Jun; 15(5-6):22-29. PubMed ID: 30013816
[No Abstract] [Full Text] [Related]
12. Assessment of Amphetamine Withdrawal Symptoms of Lisdexamfetamine Dimesylate Treatment for Adults With Binge-Eating Disorder.
Robertson B; Wu J; Fant RV; Schnoll SH; McElroy SL
Prim Care Companion CNS Disord; 2020 Mar; 22(2):. PubMed ID: 32237290
[TBL] [Abstract][Full Text] [Related]
13. Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2015 Apr; 69(4):410-21. PubMed ID: 25752762
[TBL] [Abstract][Full Text] [Related]
14. The Cost Effectiveness of Lisdexamfetamine Dimesylate for the Treatment of Binge Eating Disorder in the USA.
Ágh T; Pawaskar M; Nagy B; Lachaine J; Vokó Z
Clin Drug Investig; 2016 Apr; 36(4):305-12. PubMed ID: 26914658
[TBL] [Abstract][Full Text] [Related]
15. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
16. Lisdexamfetamine in Pediatric Binge Eating Disorder: A Retrospective Chart Review.
Guerdjikova AI; Blom TJ; Mori N; Matthews A; Cummings T; Casuto LL; McElroy SL
Clin Neuropharmacol; 2019; 42(6):214-216. PubMed ID: 31725476
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety, and tolerability of nivasorexant in adults with binge-eating disorder: A randomized, Phase II proof of concept trial.
McElroy SL; Coloma PM; Berger B; Guerdjikova AI; Joyce JM; Liebowitz MR; Pain S; Rabasa C
Int J Eat Disord; 2023 Nov; 56(11):2120-2130. PubMed ID: 37584285
[TBL] [Abstract][Full Text] [Related]
18. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
[TBL] [Abstract][Full Text] [Related]
19. Lisdexamfetamine: A Review in Binge Eating Disorder.
Heo YA; Duggan ST
CNS Drugs; 2017 Nov; 31(11):1015-1022. PubMed ID: 29134566
[TBL] [Abstract][Full Text] [Related]
20. The effects of lisdexamfetamine dimesylate on eating behaviour and homeostatic, reward and cognitive processes in women with binge-eating symptoms: an experimental medicine study.
Schneider E; Martin E; Rotshtein P; Qureshi KL; Chamberlain SR; Spetter MS; Dourish CT; Higgs S
Transl Psychiatry; 2022 Jan; 12(1):9. PubMed ID: 35013131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
